Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2013

View Archived Issues

GlaxoSmithKline presents new agents for HCV infection

CLIC3 identified as a marker of breast cancer prognosis

Scientists discover a new chimeric gene associated with myeloma

First-in-human study data reported for ACE-536

Novel phosphodiesterase inhibitors patented by Nycomed (Takeda Pharmaceutical)

Basilea Pharmaceutica discloses new antibacterial agents

Boehringer Ingelheim Pharma patents new CCR2 receptor antagonists

IntraCellular Therapies prepares novel PDE1A inhibitors

Aurigene Discovery Technologies divulges novel hPD-1 inhibitors

BrainStorm's NurOwn trial is fast-tracked to phase IIa

First-in-human phase I study begins for TGR-1202

The methodology and application of a single-cell, genome-wide analysis of genetic polymorphisms

Phase I RenaZorb data support further development

Advanced Cell Technology gives update on phase I/II stem cell trials in SMD and AMD

Takara Bio begins phase I trial of HIV-1 gene therapy

Baxter reports phase III data for FEIBA NF

FDA approves Kineret for the treatment of NOMID

Tobira Therapeutics reports data from phase IIb cenicriviroc trial

Uluru begins launch of Altrazeal in Europe

Chugai and Debiopharm enter license agreement for anticancer agent

FDA and EMA to review GE Healthcare's applications for flutemetamol (18F)

Novel allergic dermatitis model in pigs reveals activity of escin

GSK and Theravance submit MAA for umeclidinium bromide/vilanterol

Bayer's Skyla approved by FDA to prevent pregnancy for up to 3 years

Takeda launches Lotriga 2 g for the treatment of hyperlipidemia in Japan

Biocon receives marketing authorization in India for itolizumab